You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Innovative Mitigation of Radiation Effects in Advanced Technology Nodes

    SBC: MICROELECTRONICS RESEARCH DEVELOPMENT CORPORATION            Topic: DTRA16A003

    Micro-RDC has developed portable radiation effects test structures that scale to new process nodes.These structures will enable the investigation of the effects of radiation on the new technology from the material processing level as well as the circuit level.Fabricating the chosen structures and the refinement of software to extract the model parameters will be completed in this effort.A suite of ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  2. Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence

    SBC: KannaLife Sciences Inc.            Topic: NIDA

    Chemotherapy induced peripheral neuropathyCIPNcan be a chronicseverely debilitating consequence of cancer therapy for which there are no effective management strategiesMoreoverupwards ofof CIPN patients reported using prescription opioids for pain management despite the fact that there is only weak evidence that long term continuation of opioids provides clinically significant pain relief in these ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. An Engineered Nanoimmunotherapy for Melanoma

    SBC: ImmunoBlue, LLC            Topic: NCI

    PROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth

    SBC: ReveraGen BioPharma, Inc.            Topic: NICHD

    There is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant EnterobacteriaceaeCREand present significantly less therapeutic intervention optionsFurthermorecommunity acquired infections associated with hypervirulent isolates of Kpneumoniae have emerged that are ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. MtLDL detection to diagnose childhood tuberculosis

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIAID

    Project SummaryChildhood TB is estimated to contributeof the disease burden in high burden settingswith approximately a million cases per year inworldwideExisting gold standard diagnostic culture tools fail to confirm TB in most childrenwho typically have low bacterial counts and cannot produce sputumMore sensitive and child friendly diagnostic tools are urgently needed to diagnose TB in childrenC ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors

    SBC: Weinberg Medical Physics, Inc.            Topic: NIDA

    Abstract Deep brain stimulationDBSwith implantable electrodes has been used for reduction of ethanol abuse and drug seeking behaviors in EuropeThe use of such deep brain stimulation procedures has been problematic because of concerns about invasiveness of the procedureApplicant has developed a new noninvasive method of transporting magnetic particles directly to target sites within the brainWe pro ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Expansion of Immuno-CometChip Platform

    SBC: Amelia Technologies LLC            Topic: NIEHS

    Project SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Oxidation-resistant Anti-protease Therapy

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    Project Summary As part of the FDA approval process for novel therapeutic drugssafety screening demonstrating that the candidate drug does not have deleterious effects on the human cardiac action potential is requiredHealthy human heart cells are not available for such preclinical drug testingThere is currently no consensus on the best experimental approach to provide the most efficienteconomicala ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government